Lifecore Biomedical, Inc. Common Stock (LFCR) is a publicly traded Healthcare sector company. As of October 20, 2026, LFCR trades at $6.37 with a market cap of $242.22M and a P/E ratio of -5.08. LFCR moved -0.31% today. Year to date, LFCR is -17.70%; over the trailing twelve months it is -3.92%. Its 52-week range spans $3.63 to $8.98. Analyst consensus is neutral with an average price target of $6.28. Rallies surfaces LFCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lifecore Biomedical unit Lifecore Biomedical LLC extends Alcon manufacturing pact term to 2034: Lifecore Biomedical LLC amended its manufacturing agreement with Alcon, extending the term from Dec. 31, 2031, to Dec. 31, 2034, with automatic 24-month renewals unless either party gives notice.
| Metric | Value |
|---|---|
| Price | $6.37 |
| Market Cap | $242.22M |
| P/E Ratio | -5.08 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.98 |
| 52-Week Low | $3.63 |
| Volume | 559.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $128.87M |
| Net Income | $-38.72M |
| Gross Margin | 31.27% |
4 analysts cover LFCR: 0 strong buy, 0 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $6.28.